These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 5155575)

  • 1. Commentary on some technical and administrative aspects of BCG vaccination.
    Boas AV
    Bull Int Union Tuberc; 1971 Dec; 46():131-4. PubMed ID: 5155575
    [No Abstract]   [Full Text] [Related]  

  • 2. Administrative and operational aspects of BCG vaccination programmes.
    Carreon AB
    Bull Int Union Tuberc; 1971 Dec; 46():123-30. PubMed ID: 5155574
    [No Abstract]   [Full Text] [Related]  

  • 3. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective effect of BCG in experimental tuberculosis.
    Smith DW
    Adv Tuberc Res; 1985; 22():1-97. PubMed ID: 3909787
    [No Abstract]   [Full Text] [Related]  

  • 5. The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs.
    Martin C; Williams A; Hernandez-Pando R; Cardona PJ; Gormley E; Bordat Y; Soto CY; Clark SO; Hatch GJ; Aguilar D; Ausina V; Gicquel B
    Vaccine; 2006 Apr; 24(17):3408-19. PubMed ID: 16564606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [On some experimental aspects of antituberculosis vaccination with BCG].
    Di Perna A; Ciaccia A; Rabinovici A
    Lotta Tuberc; 1967; 37(3):Suppl:187-203. PubMed ID: 5252289
    [No Abstract]   [Full Text] [Related]  

  • 7. BCG vaccine responses following simultaneous immunization against influenza and tuberculosis. 2nd report.
    Zykov MP; Subbotina TI; Kaplin NN
    Z Erkr Atmungsorgane; 1981 May; 157(2):165-80. PubMed ID: 6797135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The type of vaccine].
    Blasi A
    Lotta Tuberc; 1968; 38(1):84-90. PubMed ID: 5252512
    [No Abstract]   [Full Text] [Related]  

  • 9. [The problem of specific prevention of modern tuberculosis].
    Dikiĭ IL; Cherkas GP; Dikaia EM; Derkach SA; Bazavluk AD
    Mikrobiol Zh (1978); 1984; 46(5):59-62. PubMed ID: 6443872
    [No Abstract]   [Full Text] [Related]  

  • 10. Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis.
    Sun R; Skeiky YA; Izzo A; Dheenadhayalan V; Imam Z; Penn E; Stagliano K; Haddock S; Mueller S; Fulkerson J; Scanga C; Grover A; Derrick SC; Morris S; Hone DM; Horwitz MA; Kaufmann SH; Sadoff JC
    Vaccine; 2009 Jul; 27(33):4412-23. PubMed ID: 19500523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy of live tuberculosis vaccines after presensitization with Mycobacterium avium.
    de Lisle GW; Wards BJ; Buddle BM; Collins DM
    Tuberculosis (Edinb); 2005; 85(1-2):73-9. PubMed ID: 15687030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Stability and immunogenicity of the fresh BCG vaccine applied with a new multiple puncture device (author's transl)].
    Gheorghiu M; Lagranderie M; Bredèche M
    Ann Microbiol (Paris); 1981; 132(3):307-18. PubMed ID: 7027870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Tuberculosis prevention by BCG vaccine].
    Hashimoto T
    Kekkaku; 1982 Jun; 57(6):329-34. PubMed ID: 6757514
    [No Abstract]   [Full Text] [Related]  

  • 14. Protection against tuberculosis induced by oral prime with Mycobacterium bovis BCG and intranasal subunit boost based on the vaccine candidate Ag85B-ESAT-6 does not correlate with circulating IFN-gamma producing T-cells.
    Badell E; Nicolle F; Clark S; Majlessi L; Boudou F; Martino A; Castello-Branco L; Leclerc C; Lewis DJ; Marsh PD; Gicquel B; Winter N
    Vaccine; 2009 Jan; 27(1):28-37. PubMed ID: 18977269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evaluation of the BCG vaccination program in Ciudad Juárez, Chihuahua, 1970].
    Ortiz Cruz A; Arceo J
    Salud Publica Mex; 1971; 13(5):693-9. PubMed ID: 5164495
    [No Abstract]   [Full Text] [Related]  

  • 16. Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens.
    Brodin P; Majlessi L; Brosch R; Smith D; Bancroft G; Clark S; Williams A; Leclerc C; Cole ST
    J Infect Dis; 2004 Jul; 190(1):115-22. PubMed ID: 15195250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis.
    Pym AS; Brodin P; Majlessi L; Brosch R; Demangel C; Williams A; Griffiths KE; Marchal G; Leclerc C; Cole ST
    Nat Med; 2003 May; 9(5):533-9. PubMed ID: 12692540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A new vaccine strain: MPH (Murine Praha Homogeneous), developed from Mycobacterium microti OV 247 (Wells)].
    Sula I
    Tuberkuloza; 1966; 18(1-3):275-8. PubMed ID: 16296096
    [No Abstract]   [Full Text] [Related]  

  • 19. BCG vaccination and WHO's global strategy for tuberculosis control 1948-1983.
    Brimnes N
    Soc Sci Med; 2008 Sep; 67(5):863-73. PubMed ID: 18573583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparative studies of 5 BCG substrains. 3. Anti-tuberculous resistance acquired by BCG vaccination with 5 vaccines of different origins].
    Paraschivesco M; Gheorghiu M; Bonciu C; Petrovici M; Rîmniceanu I
    Arch Roum Pathol Exp Microbiol; 1969; 28(2):545-8. PubMed ID: 5400045
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.